Wedbush Reiterates Neutral on 2seventy bio, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated a Neutral rating on 2seventy bio (NASDAQ:TSVT) and maintained a $5 price target.
June 27, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst David Nierengarten has reiterated a Neutral rating on 2seventy bio and maintained a $5 price target. This suggests that the analyst does not foresee significant short-term upside or downside for the stock.
The reiteration of a Neutral rating and maintenance of the $5 price target by Wedbush indicates that the analyst's outlook on 2seventy bio remains unchanged. This suggests stability in the stock's short-term performance, with no expected significant movements up or down.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100